Abbott Healthcare

Abbott Healthcare News

#ImplantFiles: Abbott coronary stents in 50 per cent adverse event reports for 2018

An analysis by the Indian Pharmacopoeia Commission shows they have received 290 adverse reports — of 556 reports logged so far this year — for devices manufactured by Abbott.

NPPA allows Abbott Healthcare to withdraw its latest stents

On September 8, 2017, Abbott Healthcare requested the NPPA to let it withdraw Absorb and Absorb GT1 brands of Bioresorbable Vascular Scaffold from the Indian market as “it is stopping the manufacturing” of these two brands globally because of “low commercial uptake”.


Alert on Abbott’s stent issued in India in April; drug regulator gets no adverse report yet

CDSCO on April 7 had issued a safety alert against 2 stents of Abbott Healthcare — Absorb Bioresorbable Vascular Scaffold (BVS) and Absorb GT1 BVS